Calidi Biotherapeutics, Inc.'s latest marketcap:
As of 07/29/2025, Calidi Biotherapeutics, Inc.'s market capitalization has reached $10.41 M. According to our data, Calidi Biotherapeutics, Inc. is the 40485th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 10.41 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -21,575,000 |
| Shares Out | 33.59 M |
| EPS (ttm) | -1.55 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/12/2025 |
Calidi Biotherapeutics, Inc.'s yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 07/29/2025 | $10.41 M | 19.36% | 40485 |
| 12/31/2024 | $22.21 M | -58.52% | n/a |
| 12/29/2023 | $53.55 M | -46.69% | n/a |
| 12/30/2022 | $100.46 M | -64.38% | n/a |
| 12/30/2021 | $282.04 M | n/a |
Company Profile
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States.
Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors.
The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Frequently Asked Questions
-
What is Calidi Biotherapeutics, Inc.'s (CLDI) current market cap?As of 07/29/2025, Calidi Biotherapeutics, Inc. (including the parent company, if applicable) has an estimated market capitalization of $10.41 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Calidi Biotherapeutics, Inc. (CLDI) rank globally by market cap?Calidi Biotherapeutics, Inc. global market capitalization ranking is approximately 40485 as of 07/29/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.